ABNOM
☆ Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
References
Je známe, že Q-switched Nd:YAG laser účinne lieči Otovu névu a podobné stavy. Vykonali sme štúdiu, aby sme zistili, ako dobre high-fluence 1064 nm Q-switched Nd:YAG laser funguje na mongolských škvrnách v neobvyklých oblastiach bez toho, aby spôsobil zosvetlenie pokožky. Študovali sme 61 pacientov s týmito škvrnami, celkovo sme vyšetrili 70 lézií. Polovica lézií bola ošetrená laserom, zatiaľ čo ostatné boli ponechané neošetrené na porovnanie. Výsledky sme vyhodnotili pomocou stupnice a zariadenia s názvom Mexameter® na meranie hladín melanínu. Pacienti boli sledovaní v priemere 14 mesiacov v liečebnej skupine a 18 mesiacov v skupine s pozorovaním. Na konci štúdie sme zistili významné rozdiely v skóre stupnice a hladinách melanínu medzi liečenými a neliečenými skupinami, pričom skupina liečená laserom vykazovala lepšie výsledky. High-fluence Q-switched Nd:YAG laser sa ukázal ako účinný a bezpečný pri liečbe týchto nezvyčajných mongolských škvŕn bez toho, aby spôsobil zosvetlenie pokožky.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Študovali sme účinnosť a bezpečnosť používania špecifického laserového ošetrenia pre ABNOM a skúmali sme, aké faktory môžu ovplyvniť jeho účinnosť. Pozreli sme sa na 110 pacientov, ktorí mali ABNOM a dostali od dvoch do deviatich laserových ošetrení. Zistili sme, že liečba fungovala tým lepšie, čím dlhšie sa robila, ale nie tak dobre u starších pacientov. Tiež fungoval lepšie u pacientov so svetlejšou pokožkou (typ III) a menšími postihnutými oblasťami (menej ako 10 cm2) . Melazma spolu s ABNOM znížila účinnosť liečby. Zdá sa, že na farbe alebo počte postihnutých oblastí nezáleží. Asi u 10 % pacientov sa po liečbe objavili tmavšie škvrny. Včasná viacnásobná liečba priniesla dobré výsledky. U starších pacientov s tmavšou pokožkou a tmavšími škvrnami je väčšia pravdepodobnosť, že sa po liečbe objavia tmavšie škvrny. Pre pacientov s ABNOM a melazmou je lepšie použiť laser s nižšou energiou, aby sa melazma nezhoršila.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Liečba
Bieliace prostriedky zriedka pomáhajú. Na rozdiel od melazmy je možné ABNOM zlepšiť laserovým ošetrením a nechať ho odstrániť bez recidívy. Laserové ošetrenie možno vykonať 10 až 20-krát na liečbu ABNOM.
#QS1064 laser